BDRX vs. GRI, PBLA, LSDI, NBSE, SBFM, INM, EVLO, ATNF, SPRC, and PRFX
Should you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include GRI Bio (GRI), Panbela Therapeutics (PBLA), Lucy Scientific Discovery (LSDI), NeuBase Therapeutics (NBSE), Sunshine Biopharma (SBFM), InMed Pharmaceuticals (INM), Evelo Biosciences (EVLO), 180 Life Sciences (ATNF), SciSparc (SPRC), and PainReform (PRFX). These companies are all part of the "pharmaceutical preparations" industry.
GRI Bio (NASDAQ:GRI) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
Biodexa Pharmaceuticals received 1 more outperform votes than GRI Bio when rated by MarketBeat users.
Biodexa Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 733.33%. Given GRI Bio's higher possible upside, analysts plainly believe Biodexa Pharmaceuticals is more favorable than GRI Bio.
34.0% of GRI Bio shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 3.0% of GRI Bio shares are held by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, GRI Bio had 3 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 7 mentions for GRI Bio and 4 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 1.32 beat GRI Bio's score of 0.75 indicating that GRI Bio is being referred to more favorably in the media.
GRI Bio's return on equity of 0.00% beat Biodexa Pharmaceuticals' return on equity.
GRI Bio has a beta of -1.55, meaning that its stock price is 255% less volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
Biodexa Pharmaceuticals has higher revenue and earnings than GRI Bio.
Summary
Biodexa Pharmaceuticals beats GRI Bio on 8 of the 12 factors compared between the two stocks.
Get Biodexa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodexa Pharmaceuticals Competitors List
Related Companies and Tools
